News
NRSNW
0.3000
+100.00%
0.1500
Weekly Report: what happened at NRSNW last week (1118-1122)?
Weekly Report · 4d ago
BRIEF-Neurosense Therapeutics Files For Offering Of Up To 10 Million Ordinary Shares
Reuters · 11/19 22:25
Weekly Report: what happened at NRSNW last week (1111-1115)?
Weekly Report · 11/18 09:55
Weekly Report: what happened at NRSNW last week (1104-1108)?
Weekly Report · 11/11 10:01
Weekly Report: what happened at NRSNW last week (1028-1101)?
Weekly Report · 11/04 10:00
NEUROSENSE: IN CANADA, PLANS TO SUBMIT DOSSIER IN Q2 2025, WITH REGULATORY DECISION ON COMMERCIALIZATION EXPECTED BY Q1 2026
Reuters · 10/28 12:31
Weekly Report: what happened at NRSNW last week (1021-1025)?
Weekly Report · 10/28 09:57
Neurosense Therapeutics Ltd: Report of foreign issuer
Press release · 10/25 12:10
Weekly Report: what happened at NRSNW last week (1014-1018)?
Weekly Report · 10/21 09:56
NEUROSENSE THERAPEUTICS LTD: DOSSIER SUBMISSION PLANNED FOR Q2 2025; REGULATORY DECISION EXPECTED BY Q1 2026
Reuters · 10/15 13:15
Weekly Report: what happened at NRSNW last week (1007-1011)?
Weekly Report · 10/14 10:07
NEUROSENSE THERAPEUTICS: PLANS TO SEEK APPROVAL IN ADDITIONAL COUNTRIES
Reuters · 10/09 13:00
NEUROSENSE THERAPEUTICS PLANS TO FILE FOR EARLY COMMERCIALIZATION OF ALS TREATMENT IN CANADA
Reuters · 10/09 13:00
Weekly Report: what happened at NRSNW last week (0930-1004)?
Weekly Report · 10/07 10:02
Weekly Report: what happened at NRSNW last week (0923-0927)?
Weekly Report · 09/30 10:00
NEUROSENSE THERAPEUTICS LTD: PATENT PROTECTION EXTENDS THROUGH 2042, ADDING 4 ADDITIONAL YEARS TO PRIMEC'S IP UMBRELLA
Reuters · 09/24 13:05
Weekly Report: what happened at NRSNW last week (0916-0920)?
Weekly Report · 09/23 09:59
Weekly Report: what happened at NRSNW last week (0909-0913)?
Weekly Report · 09/16 09:55
Neurosense Therapeutics Ltd: Report of foreign issuer
Press release · 09/09 12:08
More
Webull provides a variety of real-time NRSNW stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSNW
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease